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Abstract 
Background: An extensive crosstalk co‑regulates the Hippo and Wnt pathway. Preclinical studies revealed that the 
Hippo transducers YAP/TAZ mediate a number of oncogenic functions in gastric cancer (GC). Moreover, comprehen‑
sive characterization of GC demonstrated that the Wnt pathway is targeted by oncogenic mutations. On this ground, 
we hypothesized that YAP/TAZ‑ and Wnt‑related biomarkers may predict clinical outcomes in GC patients treated with 
chemotherapy.
Methods: In the present study, we included 86 patients with advanced GC treated with first‑line chemotherapy in 
prospective phase II trials or in routine clinical practice. Tissue samples were immunostained to evaluate the expres‑
sion of YAP/TAZ. Mutational status of key Wnt pathway genes (CTNNB1, APC and FBXW7) was assessed by targeted 
DNA next‑generation sequencing (NGS). Survival curves were estimated and compared by the Kaplan–Meier prod‑
uct‑limit method and the log‑rank test, respectively. Variables potentially affecting progression‑free survival (PFS) were 
verified in univariate Cox proportional hazard models. The final multivariate Cox models were obtained with variables 
testing significant at the univariate analysis, and by adjusting for all plausible predictors of the outcome of interest 
(PFS).
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Background
Over the past two decades, a wave of studies in flies elu-
cidated the central role of the Hippo pathway in organ 
development [1]. Ablation of a set of genes including 
Warts (wts), Hippo (hpo), Salvador (sav) and Mob as 
tumor suppressor (mats) led to a remarkable tissue over-
growth, a process tied to increased cellular proliferation 
and reduced apoptosis [2–11]. These alterations were 
phenocopied upon the forced over-expression of the 
transcriptional co-activator Yorkie (yki) [12]. Comple-
mented by functional and biochemical evidence, studies 
in Drosophila deciphered the functional architecture of 
the “Salvador–Warts–Hippo” (SWH) pathway, and have 
been instrumental for characterizing the Hippo path-
way in mammals. Indeed, the use of conditional knock-
out alleles and inducible transgenic  mice revealed that 
manipulation of Hippo pathway components resulted 
in tissue overgrowth and tumorigenesis [13, 14]. Func-
tionally, Hippo is organized into a core regulatory mod-
ule and a transcriptional module. The first is composed 
by the kinases sterile 20-like kinase 1 and 2 (MST1 and 
MST2; Hpo in Drosophila) and large tumor suppressor 1 
and 2 (LATS1 and LATS2, Wts in Drosophila), together 
with the adaptor proteins Salvador homolog 1 (SAV1; 
Sav in Drosophila) and MOB kinase activator 1A and 1B 
(MOB1A and MOB1B; Mats in Drosophila). The latter 
encompasses the transcriptional cofactors yes-associated 
protein and its paralog transcriptional co-activator with 
PDZ-binding motif (YAP and TAZ, respectively; Yki in 
Drosophila), along with their transcriptional partners 
TEA domain-containing sequence-specific transcrip-
tion factors (TEAD1-4; Scalloped in Drosophila) [1]. 
The core module orchestrates a phosphorylation cas-
cade that results in the inhibition of YAP/TAZ, promot-
ing their nuclear exclusion, cytoplasmic retention and 
proteasomal degradation [14–18]. When inactivated, or 
in the presence of stimuli that bypass its function, YAP/
TAZ accumulate into the nucleus, interact with their 
transcriptional partners and ultimately promote the tran-
scription of target genes. Given that loss-of-function of 
Hippo kinases and adaptors fuelled tumor formation 
in animal models, and a similar outcome was observed 
upon the forced expression of Hippo transducers, Hippo 
was designated as a tumor suppressive signaling deputed 
to inhibit the oncogenic proteins YAP and TAZ [1].
Hippo signaling lies at the centerpiece of an intricate 
molecular network [19, 20]. Indeed, a number of regu-
latory branches modulate its activity, spanning from 
cell polarity and cell adhesion factors to kinases act-
ing upstream the regulatory module, mechanical forces 
(mechanotransduction), G-protein-coupled receptors 
(GPCRs) and metabolic routes [1]. An emerging level 
of regulation refers to the cooperation between Hippo 
and the Wnt pathway [1]. Central in the regulation of 
the Wnt signaling is the β-catenin destruction complex 
[21]. This is composed by a set of proteins that, in the 
absence of Wnt ligand stimulation, retains β-catenin in 
the cytoplasm and enables its degradation, thus prevent-
ing β-catenin nuclear translocation and transcription of 
target genes [21]. The crosstalk between Hippo and Wnt 
prevalently takes place at the level of β-catenin regula-
tion [22, 23]. Two not mutually exclusive models have 
been proposed that functionally concatenate these two 
pathways. The first envisions the incorporation of YAP/
TAZ in the β-catenin destruction complex [22]. When 
the Wnt pathway is in the off state, YAP/TAZ participate 
in β-catenin degradation, whereas stimulation by Wnt 
ligands disassembles the complex promoting nuclear 
accumulation of both YAP/TAZ and β-catenin [22]. 
The second model proposes that Adenomatosis Poly-
posis Coli (APC), a central component of the β-catenin 
destruction complex, serves as a scaffold protein whose 
correct function is instrumental for the activation of 
Hippo kinases and consequent inhibition of YAP/TAZ 
[23]. Consistently, loss of APC disables Hippo-mediated 
control of YAP/TAZ [23].
Functional in vitro and in vivo studies linked aberrant 
activation of YAP/TAZ to the progression of gastric can-
cer (GC) [24], and the inhibition of the YAP/TAZ–TEAD 
interaction achieved with a Vgl-like-4—(VGLL4) mim-
icking peptide severely impaired GC cell survival [25]. 
Moreover, the comprehensive characterization of GC 
Results: We observed a significant association between TAZ expression and Wnt mutations (Chi‑squared p = 0.008). 
Combined TAZ expression and Wnt mutations  (TAZpos/WNTmut) was more frequently observed in patients with the 
shortest progression‑free survival (negative outliers) (Fisher p = 0.021). Uni‑and multivariate Cox regression analyses 
revealed that patients whose tumors harbored the  TAZpos/WNTmut signature had an increased risk of disease progres‑
sion (univariate Cox: HR 2.27, 95% CI 1.27–4.05, p = 0.006; multivariate Cox: HR 2.73, 95% CI 1.41–5.29, p = 0.003). 
Finally, the  TAZpos/WNTmut signature negatively impacted overall survival.
Conclusions: Collectively, our findings indicate that the oncogenic YAP/TAZ–Wnt crosstalk may be active in GC, 
conferring chemoresistant traits that translate into adverse survival outcomes.
Keywords: Gastric cancer, Hippo pathway, YAP, TAZ, Wnt pathway, CTNNB1, APC, FBXW7
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carried out by The Cancer Genome Atlas (TCGA) net-
work revealed oncogenic mutations in central Wnt path-
way components, including CTNNB1 (β-catenin), APC 
and FBXW7 (F-box/WD repeat domain-containing 7), an 
antagonist of the Wnt signaling that targets β-catenin for 
degradation [26]. On this ground, we hypothesized that 
the Hippo–Wnt pathway crosstalk may be active in GC, 
conferring more aggressive molecular traits that translate 
into adverse survival outcomes. To test this hypothesis, 
tissue samples from 86 GC patients treated with first-line 
chemotherapy, either in prospective phase II trials or in 
routine clinical practice [27–30], were retrospectively 
evaluated by immunohistochemistry (IHC) for assessing 
the expression of YAP and TAZ. Immunohistochemical 
characterization was integrated with targeted DNA next-
generation sequencing (NGS) analysis of CTNNB1, APC 
and FBXW7.
Methods
Patients and treatment
In the present study, we included 86 patients with his-
tologically confirmed, inoperable locally advanced or 
metastatic cancer of the stomach or gastroesophageal 
junction who received first-line chemotherapy (August 
2001–June 2015). Median follow-up was 11 months (IQR 
5.5–20.5  months). Eligibility was defined by the follow-
ing criteria: (i) available data on clinical features, admin-
istered therapies and treatment outcomes, (ii) complete 
data on protein biomarkers (YAP and TAZ), and (iii) 
complete data on Wnt pathway component mutations. 
Chemotherapy regimens and schedules are detailed in 
Additional file  1. Tumor responses were evaluated by 
Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria v.1.1. Progression-free survival (PFS) was calcu-
lated as the time between the first cycle of chemother-
apy and radiological evidence of disease progression or 
death due to any cause. Overall survival (OS) was com-
puted as the time from the first cycle of chemotherapy to 
death from any cause, and as the time from diagnosis to 
death due to any cause. Written informed consents were 
obtained by all the participants. The study was conducted 
in accordance with the Declaration of Helsinki and 
approved by the Ethics Committee of the “Regina Elena” 
National Cancer Institute of Rome. This study adheres to 
the REMARK guidelines [31].
Immunohistochemical assessment of YAP and TAZ
The immunohistochemical assessment of YAP and TAZ 
was performed in formalin-fixed paraffin-embedded 
(FFPE) tissues from biopsies or surgical samples, and 
was carried out with the following antibodies: anti-YAP 
monoclonal antibody (MoAb) (H-9, Santa Cruz) at the 
dilution of 1:200 and anti-TAZ MoAb (M2-616, BD 
Pharmingen) at the dilution of 1:400. Immunoreactions 
were revealed by a streptavidin–biotin enhanced immu-
noperoxidase technique (Super Sensitive MultiLink, 
Leica, Milan, Italy) in an automated autostainer (Bond 
III, Leica). YAP/TAZ expression was reported both in 
terms of percentage of tumor-expressing cells and stain-
ing intensity (0 =  absent, 1+ =  weak, 2+ =  moderate, 
and 3+  =  strong). For tumors with both nuclear and 
cytoplasmic expression, staining intensity and percentage 
of tumor-expressing cells were independently assessed in, 
and reported for, the two cellular compartments. Tumors 
were classified as negative  (YAPneg,  TAZneg) or positive 
 (YAPpos,  TAZpos) on the basis of cellular localization and 
percentage of tumor-expressing cells. YAP/TAZ positiv-
ity was defined as a distinct nuclear immunoreactivity 
in ≥ 20% of neoplastic cells, a classification comparable 
to that of our previous studies [32–34]. Representative 
examples of immunohistochemical expression of YAP/
TAZ is provided in Additional file  2. Immunoreactiv-
ity was evaluated by two investigators blinded to treat-
ment outcomes (EM and LR), and discordant cases were 
reviewed by a third observer (MM).
Targeted DNA NGS
DNA was extracted from FFPE tumor blocks using 
the QIAamp DNA Mini Kit (Qiagen). Quantity of the 
extracted DNA was assessed by the Qubit dsDNA High 
Sensitivity Assay Kit on Qubit Fluorometer (Ther-
mofisher Scientific). Library preparation was performed 
on 20  ng DNA by the Ion AmpliSeq Library 96LV Kit 
2.0 (Thermofisher Scientific) and the Wnt custom panel 
(Thermofisher Scientific), which targets 3 genes (APC, 
CTNNB1 e FBXW7) and generates 174 amplicons (mean 
coverage: 98.8%). Each library was barcoded with the Ion 
Xpress Barcode Adapters 1–16 Kit (Thermofisher Sci-
entific) and diluted to a final concentration of 100  pM; 
barcoded libraries were pooled in equimolar amount and 
diluted to 35 pM for downstream template preparation. 
Template preparation was performed by the Ion Chef 
system (Thermofisher Scientific), which integrates library 
amplification, ISP recovery-enrichment and Chip load-
ing. Sequencing was performed on Ion S5 system (Ther-
mofisher Scientific) with the Ion 520 chip. Raw data were 
analyzed using the Torrent Suite Software v.5.2 (Ther-
mofisher Scientific). The coverage analysis was performed 
using the coverage analysis plug-in v5.2.1.2. All cases had 
a number of mapped reads > 100.000 and/or the average 
base coverage > 500×. Polymorphic variants were filtered 
out exploiting the Ion Reporter Suite (Thermofisher Sci-
entific). Nucleotide variants with an allele frequency less 
than 3% were not considered. All variants were manually 
reviewed with Integrative Genomics Viewer (IGV V.2.1, 
Broad Institute, Cambridge, Massachusetts, USA), and 
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with the support of publically available datasets reporting 
on their established or predicted oncogenicity (i.e. COS-
MIC, OncoKB and Mutation Assessor via cBioPortal). 
All molecular analyses were carried out in tissue samples 
collected before the administration of first-line chemo-
therapy for advanced disease.
Statistical analysis
Descriptive statistics were computed for all the variables 
of interest (clinical, pathological and molecular). The 
relationship between categorical variables was assessed 
with the Pearson’s Chi squared test of independence 
(2-tailed) or the Fisher exact test, depending upon the 
size of the groups compared. The Kaplan–Meier prod-
uct-limit method and the log-rank test were used for 
estimating and comparing survival curves. Variables 
potentially affecting PFS were tested in univariate Cox 
proportional hazard models (ECOG-PS: 0 vs 1–2; stage: 
locally advanced vs metastatic; localization: stomach vs 
junction; number of metastatic sites: 1 vs 2–3; peritoneal 
metastasis: no vs yes; first-line taxane-containing chemo-
therapy: no vs yes; γ-H2AX/pATM: negative/single posi-
tive vs double positive) [35]. The final multivariate Cox 
models were obtained with variables testing significant at 
the univariate analysis, and by adjusting for all plausible 
predictors of the outcome of interest (PFS). The related 
estimates were reported as hazard ratio (HR) and 95% 
confident interval (CI). The consistency of the  TAZpos/
WNTmut model was assessed through a re-sampling 
without replacement method (internal validation). More 
specifically, 100 hundred, less-powered datasets were 
generated by randomly removing ~ 20% from the original 
sample. For each simulation, the univariate Cox model 
was repeated and the replication rate was calculated. 
Level of significance was defined at p  <  0.05. Statistical 
analyses were carried out using SPSS version 21.0 (SPSS 
Inc., Chicago, Illinois, USA).
Results
Baseline characteristics of the study participants
Baseline characteristics of the 86 patients included in the 
present study are summarized in Table 1. Median age at 
diagnosis was 61 years (IQ range 53.6–67.6). 36 (41.9%) 
and 50 (58.1%) patients had a locally advanced or meta-
static disease, respectively. 50 (58.1%) patients received 
three-drug chemotherapy, and taxane-containing regi-
mens were administered to 47 (54.7%) patients. In this 
series, 42 (48.8%) patients were treated within the con-
text of prospective phase II trials. We did not record any 
significant association between the investigational bio-
markers (YAP, TAZ, Wnt mutations) and basal clinical 
and pathological characteristics detailed in Table 1 (data 
available upon request).
Relationship between YAP/TAZ expression and Wnt 
mutations
The individual distribution of the molecular biomark-
ers evaluated in the present study is illustrated in Fig. 1a. 
YAP and TAZ positivity was observed in 76 (88.4%) 
and 35 (40.7%) tumor samples, respectively. Muta-
tions of CTNNB1, APC and FBXW7 were detected in 
9 (10.5%), 20 (23.2%), and 17 (19.8%) tumor samples, 
respectively. When considering integrated pathway 
analysis, 30 (34.9%) tumors carried at least one muta-
tions in Wnt pathway genes (Fig. 1a). Overall, 95 muta-
tions were detected: CTNNB1 N = 14, APC N = 45 and 
FBXW7 N = 36 (Fig. 1b). In the search of predictive fac-
tors, we first sought to address the relationship between 
Table 1 Baseline characteristics of gastric cancer patients 
included in this study (N = 86)
Characteristics N (%)
Age at diagnosis, median (min–max) [IQ range] 61 (28–79) [53.6–67.6]
Gender
 Male 44 (51.2)
 Female 42 (48.8)
ECOG PS
 0 45 (52.3)
 1–2 41 (47.7)
Stage
 Locally advanced 36 (41.9)
 Metastatic 50 (58.1)
Previous surgery
 No 33 (38.4)
 Yes 53 (61.6)
Neoadjuvant/adjuvant chemotherapy
 No 61 (70.9)
 Yes 25 (29.1)
Lauren classification
 Intestinal 35 (40.7)
 Diffuse 41 (47.7)
 Mixed 10 (11.6)
Grade
 G2 21 (24.4)
 G3 65 (75.6)
Localization
 Esophagogastric junction 6 (7.0)
 Stomach 80 (93.0)
Agents (N)
 2 36 (41.9)
 3 50 (58.1)
Taxanes (first‑line)
 No 39 (45.3)
 Yes 47 (54.7)
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the various investigational biomarkers. We observed 
a significant association between nuclear TAZ expres-
sion and the presence of Wnt mutations (Chi-squared 
p =  0.008) (Table  2). Prompted by this observation, we 
conducted an outlier analysis in the attempt of identi-
fying molecular features that characterize exceptional 
responders and patients with intrinsically chemoresistant 
disease. Thus, we verified the distribution of YAP, TAZ, 
and Wnt mutations in negative and positive outliers, 
defined as patients in the lowest (PFS < 3.3 months) and 
highest (PFS  ≥  11.0  months) quartile (N  =  43). When 
Fig. 1 a Oncoprint showing the distribution of the investigated biomarkers (YAP, TAZ, CTNNB1, APC, FBXW7) together with the cases with at least 
one mutations in Wnt pathway components (integrated pathway analysis). b MutationMapper illustrating the entire set of detected mutations (and 
their nature) represented on the linear proteins
Table 2 Association between the expression of YAP/TAZ 
and Wnt pathway mutations (N = 86)
WNT p-value
WT MUT
N (%) N (%)
TAZneg 39 (76.5) 12 (23.5) 0.008 (Chi‑squared)
TAZpos 17 (48.6) 18 (51.4)
YAPneg 7 (70.0) 3 (30.0) 0.999 (Fisher)
YAPpos 49 (64.5) 27 (35.5)
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biomarkers were individually considered, only TAZ was 
significantly more expressed in the negative outlier group 
(Chi-squared p = 0.044) (Table 3). However, the strong-
est association was observed when we tested a signature 
that combined nuclear TAZ expression and Wnt muta-
tions  (TAZpos/WNTmut), which was significantly overrep-
resented in the negative outlier group (Fisher p = 0.021) 
(Table 3). Considering the significant association between 
nuclear TAZ expression and Wnt pathway mutations 
(Table  2), results from the outlier analysis that indicate 
a different distribution of the  TAZpos/WNTmut signature 
between negative and positive outliers (Table 3), and tak-
ing into account the biological plausibility of the  TAZpos/
WNTmut model, this molecular profile was further inves-
tigated for its impact on survival outcomes.
Association between the  TAZpos/WNTmut signature 
and survival outcomes
Patients whose tumors carried the  TAZpos/WNTmut sig-
nature experienced significant shorter PFS compared 
with their negative counterparts (log rank p  =  0.004) 
(Fig.  2). In the univariate Cox regression analyses, the 
 TAZpos/WNTmut signature was the only variable associ-
ated with an increased risk of progression (HR 2.27, 95% 
CI 1.27–4.05, p = 0.006) (Table 4), together with a DNA 
damage repair signature we previously developed in a 
larger cohort of 110 GC patients (the γ-H2AXpos/pATM-
pos model) [35]. In the multivariate Cox models obtained 
by adjusting for all the plausible predictors tested in uni-
variate analysis, the  TAZpos/WNTmut signature remained 
associated with an increased risk of disease progression 
(HR 2.73, 95% CI 1.41–5.29, p = 0.003) (Table 4). Com-
parable results emerged when exclusively adjusting for 
the γ-H2AXpos/pATMpos signature (HR 2.21, 95% CI 
1.23–3.97, p =  0.008) (Table  4). Collectively, these data 
indicate that the  TAZpos/WNTmut signature confers an 
increased risk of disease progression, and suggest that 
two independent molecular predictors were identified 
 (TAZpos/WNTmut and γ-H2AXpos/pATMpos). Upon resa-
mpling (procedure detailed in “Statistical analyses” sec-
tion), the replication rate for the univariate Cox model 
for PFS was 84%, thus indicating the stability of the 
model. Finally, the  TAZpos/WNTmut signature was asso-
ciated with inferior overall survival, albeit to a not fully 
significant extent (log rank p =  0.076) (Fig.  3a). Never-
theless, this association became fully significant when OS 
was computed from the time of diagnosis instead of date 
at the initiation of chemotherapy (log rank p  =  0.035) 
(Fig.  3b), suggesting that the  TAZpos/WNTmut signature 
may hold both predictive and prognostic significance.
Discussion
In the present study, we examined the expression of the 
Hippo transducers YAP/TAZ together with mutations 
in central components of the Wnt pathway in a rela-
tively large series of advanced GC patients treated with 
chemotherapy in the first-line setting. Approximately half 
of the patients examined were treated in the context of 
prospective phase II trials [27–30]. This study, which is 
hypothesis-generating by nature, capitalizes on a grow-
ing body of evidence that converge on assigning to the 
Hippo–Wnt pathway cooperation a central role in three 
intertwined processes, namely organ development, tis-
sue repair after injuries and tumorigenesis [22, 23]. Col-
lectively, our results indicate that: (i) a subset of GC is 
characterized by a signature denoting deregulation of 
both Hippo and Wnt, (ii) the coexistence of nuclear 
TAZ expression and pathogenic Wnt pathway mutations 
seems to be predictive of shorter PFS, and then reduced 
efficacy of first-line chemotherapy, and (iii) the  TAZpos/
WNTmut signature may also represent an adverse prog-
nostic factor. To our knowledge, this is the first report 
striving to address the clinical significance of the Hippo–
Wnt crosstalk in GC. Earlier studies suggested that YAP/
TAZ are often expressed in GC, which is consistent with 
our data [24, 36–38]. Nevertheless, studies reported so 
far have described small-sized case series without a clear 
focus on therapeutic outcomes (e.g. by pooling data con-
cerning patients with various disease stages and progno-
sis), or have been conducted in specific disease entities 
which are not necessarily representative for the overall 
category of advanced GC (e.g. signet ring cell carcinoma, 
gastroesophageal junction cancers) [24, 36–38].
In our opinion, our findings raised a number of points 
that may streamline the identification of Hippo/Wnt-
related predictive factors in GC. First, the molecular 
characterization of GC delineated four distinct molecular 
Table 3 Association between Hippo- and Wnt-related bio-
markers and positive/negative outliers (N = 43)
* Fisher’s exact test
PFS (outliers) Chi-squared test
< 1 quartile > 3 quartile p-value
N (%) N (%)
TAZneg 10 (37.0) 17 (63.0) 0.044
TAZpos 11 (68.8) 5 (31.3)
YAPneg 2 (40.0) 3 (60.0) 0.999*
YAPpos 19 (50.0) 19 (50.0)
WNTwt 11 (39.3) 17 (60.7) 0.087
WNTmut 10 (66.7) 5 (33.3)
Other 14 (40.0) 21 (60.0) 0.021*
TAZpos/WNTmut 7 (87.5) 1 (12.5)
Other 12 (41.4) 17 (58.6) 0.159
YAPpos/WNTmut 9 (64.3) 5 (35.7)
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subtypes: chromosomal instability (CIN), microsatellite 
instability (MSI), genomically stable (GS) and Epstein–
Barr virus (EBV)-positive [26]. Mutations in Wnt pathway 
components were observed across all non-hypermutated 
subtypes. Conversely, hallmarks of GS–GC are RHOA 
and CDH1 mutations, together with CLDN18–ARH-
GAP26 fusions. All these alterations suggest genetically-
driven deregulation of the Hippo pathway. Indeed, Rho 
GTPases are involved in the activation of YAP/TAZ and 
in the inhibition of Hippo kinases via two distinct mecha-
nisms: (i) stimulation by soluble factors that act through 
G-protein-coupled receptors (GPCRs) and Rho GTPases 
[39–43], and (ii) mechanical cues, such as extracellular 
matrix stiffness and changes in cell geometry, attachment 
status and density, that regulate YAP/TAZ through Rho 
GTPases and the remodeling of the F-actin cytoskeleton 
[44–46]. Next, CDH1 encodes for the cell–cell adhesion 
molecule E-cadherin, the central component of adherens 
junctions. E-cadherin is an established positive regulator 
of MST1/2 activity, whereas the E-cadherin-associated 
protein α-catenin sequesters YAP/TAZ in the cytoplasm, 
hindering their nuclear translocation [47–49]. Consist-
ently, disruption of the E-cadherin–catenin complex at 
the cell–cell junction fuels YAP/TAZ activation [47–49]. 
Finally, the CLDN18–ARHGAP26 fusion implies defects 
in CLDN18 and ARHGAP26. CLDN18 encodes for 
Claudin 18, a component of tight junctions (TJs) [50]. 
TJ proteins promote activation of Hippo kinases and/
or sequester YAP/TAZ in the cytoplasm, whereas ARH-
GAP26 encodes for the Rho-Type GTPase-Activating 
Protein 26 [51–57]. These observations suggest that 
GS–GC is characterized by multiple defects in cell–cell 
adhesion mechanisms that, in turn, can propel YAP/TAZ 
activation. Different considerations apply to EBV-related 
GC. Experimental models of liver and cervical tumors are 
beginning to shed light on the connection between viral 
proteins and YAP/TAZ. For instance, the hepatitis B virus 
X protein (HBx) up-regulates YAP promoting the growth 
Fig. 2 Kaplan–Meier survival curves of progression‑free survival comparing  TAZpos/WNTmut cases versus their negative counterparts (N = 86)
Page 8 of 11Melucci et al. J Transl Med  (2018) 16:22 
of hepatoma cells, whereas in hepatocellular carcinoma 
cell lines the transcriptional activator PreS2 up-regulates 
TAZ via the suppression of miRNA-338-3p [58, 59]. Like-
wise, in cervical cancer cells the HPV E6 protein protects 
YAP from proteasome-dependent degradation in a pro-
cess that ignites cancer cell proliferation [60]. Remark-
ably, a distinctive feature of EBV-associated GC is the 
extreme DNA hypermethylation, and both MOB1B and 
WWTR1 (the gene encoding for TAZ) present frequent 
promoter hypermethylation [26]. Thus, more tailored 
investigations are needed in the future, which specifically 
take into account the molecular classification of GC and 
the underlying molecular portraits characterizing the dif-
ferent subtypes.
Another aspect that deserves mention is that the activ-
ity of Hippo and Wnt is modulated by negative feedback 
loops. Indeed, the YAP/TAZ–TEADs and β-catenin-
TCF/LEF complexes also promote the transcription 
of negative pathway regulators [61, 62]. For instance, 
the YAP/TAZ–TEADs complex controls the activity 
of Hippo kinases by inducing the expression of LATS2, 
and mediates the transcription of neurofibromin 2 (NF2, 
also known as Merlin), an established positive regulator 
of LATS1/2 kinase activity [61]. Aware of these mecha-
nisms, our original experimental workflow envisioned 
targeted RNA sequencing for evaluating two signatures 
denoting the activation of YAP/TAZ and Wnt. The logic 
behind this was to carry out an extensive characterization 
at three different levels (protein, transcript and gene), 
which would have enabled us to investigate negative 
feedback loops. Even though this task was halted owing 
to excessive RNA degradation in the majority of samples, 
transcript-level analysis will be further pursued in future 
studies from our research team.
Finally, Hippo and Wnt are two pieces of a wider cross-
regulation process involving multiple signaling pathways 
[i.e. Hedgehog, Notch and Bone Morphogenetic Protein 
(BMP)], whose activity is central in organ development, 
tissues homeostasis, stem cell fate and tumorigenesis [19, 
20]. Albeit these pathways are not targeted by genetic 
events in GC [26], the evaluation of biomarkers function-
ing as readout for their activation may add further granu-
larity, allowing the evaluation of co-regulated signaling 
avenues.
Conclusions
Our data pointed to the combined activation of two onco-
genic avenues, YAP/TAZ and Wnt, as potential biomark-
ers for predicting the efficacy of chemotherapy in GC 
patients. Considering the intricate molecular network 
Table 4 Uni- and multivariate Cox regression models for PFS (N = 86)
a Adjusted for the variables significant at the univariate analysis
b Adjusted for all the variables tested at univariate analysis
Univariate Cox regression model Multivariate Cox regression  modela Multivariate Cox regression 
 modelb
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
γ‑H2AXpos/pATMpos
 Positive vs other 2.14 (1.30–3.53) 0.003 2.09 (1.27–3.45) 0.004 1.87 (1.04–3.39) 0.038
TAZpos/WNTmut
 Positive vs other 2.27 (1.27–4.05) 0.006 2.21 (1.23–3.97) 0.008 2.73 (1.41–5.29) 0.003
ECOG‑PS
 1–2 vs 0 1.23 (0.77–1.97) 0.391 1.20 (0.73–1.95) 0.471
Stage
 Met vs loc adv 1.12 (0.69–1.80) 0.647 0.89 (0.46–1.73) 0.737
Localization
 Stomach vs EOJ 0.67 (0.27–1.69) 0.398 1.54 (0.53–4.42) 0.424
Number of metastatic sites
 2–3 vs 1 1.57 (0.93–2.65) 0.089 1.33 (0.70–2.50) 0.379
Peritoneal metastasis
 Yes vs No 0.67 (0.42–1.07) 0.097 0.72 (0.41–1.27) 0.261
Taxanes
 Yes vs No 0.93 (0.58–1.51) 0.784 0.79 (0.45–1.40) 0.429
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Fig. 3 Kaplan–Meier survival curves of overall survival comparing  TAZpos/WNTmut cases versus their negative counterparts (N = 86). a Refers to 
overall survival calculated from the first cycle of chemotherapy, whereas b illustrates overall survival calculated from diagnosis
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that co-regulates YAP/TAZ and Wnt, we believe that 
more comprehensive, subtype-restricted, pathway analy-
ses will be instrumental to gain a better understand-
ing on the Hippo–Wnt pathway crosstalk and its clinical 
implications.
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